Cyclo Therapeutics, a clinical stage biotechnology company, completed the merger with Applied Molecular Transport, a biopharmaceutical company. Financial terms were not disclosed. “The completion of this merger with Applied Molecular Transport represents a significant milestone and bolsters our confidence and excitement for the future of Cyclo Therapeutics. With the merger now closed and following our recent positive Type C meeting with the FDA, fundamentally the Company has never been stronger. Moving forward, we are focused on completing our Phase 3 study and executing on the regulatory submission process, assuming a successful outcome in our pivotal study. We remain dedicated to providing a much-needed treatment option for NPC patients," N. Scott Fine, Cyclo Therapeutics CEO.